BRCA基因突变卵巢癌的治疗进展  

Advances in the treatment of ovarian cancer with BRCA gene mutation

作　　者：张雅娣 周艳丽 李华梅 冯彦丽[2] Zhang Yadi;Zhou Yanli;Li Huamei;Feng Yanli(Clinical Medical College of Jining Medical University,Jining 272000,China;Department of Gynecology,Affiliated Hospital of Jining Medical University,Jining 272000,China)

机构地区：[1]济宁医学院临床医学院,272000 [2]济宁医学院附属医院妇科,272000

出　　处：《中国综合临床》2021年第5期470-473,共4页Clinical Medicine of China

基　　金：济宁医学院贺林院士新医学临床转化工作站科研基金 (JYHL2018FMS20)。

摘　　要：卵巢癌是女性生殖系统肿瘤中最为致命的恶性肿瘤,大多在晚期被诊断出来,这在很大程度上导致了卵巢癌的预后不佳。乳腺癌易感基因(breast cancer susceptibility genes,BRCA)是一种重要的DNA同源修复基因,在正常的细胞DNA修复机制中起主要作用,其突变会导致同源重组缺陷,从而影响基因组的稳定性,导致肿瘤的发生。近年来,BRCA基因检测已经成为卵巢癌风险评估、预后、治疗和预防的关键步骤。Ovarian cancer is the most fatal malignant tumor in female reproductive system tumors.In most women,it is diagnosed in a late stage,which largely leads to the poor prognosis of ovarian cancer.Breast cancer susceptibility gene(BRCA)is an important DNA homologous repair gene,which plays a major role in the normal cellular DNA repair mechanism.Its mutation will lead to homologous recombination defects,which will affect the stability of the genome and lead to occurrence of tumors.In recent years,BRCA genetic testing has become a key step in the risk assessment,prognosis,treatment and prevention of ovarian cancer.

关 键 词：卵巢癌 乳腺癌易感基因 突变 治疗 

分 类 号：R737.31[医药卫生—肿瘤]